COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma (BJCH-MM-0624)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03941795
Recruitment Status : Recruiting
First Posted : May 8, 2019
Last Update Posted : December 6, 2019
Information provided by (Responsible Party):
Jun Guo, Beijing Cancer Hospital

Brief Summary:
This is a randomized, controlled, multicenter Phase II clinical study to evaluate the efficacy and safety of toripalimab injection combined with axitinib in the first-line treatment of patients with advanced mucosal melanoma. The target population is the patients with previously untreated, histopathologically confirmed, unresectable or metastatic mucosal melanoma. At the randomization, patients are randomized 1:1:1 into three groups with approximately 33 subjects in each group to receive toripalimab injection plus axitinib, toripalimab injection monotherapy (subjects who meet the criteria after disease progression may cross over to receive toripalimab plus axitinib), or axitinib monotherapy (subjects who meet the criteria after disease progression may cross over to receive toripalimab plus axitinib); when the patient has disease progression or intolerable toxicity, the treatment is terminated, and the survival follow-up will be initiated.

Condition or disease Intervention/treatment Phase
Advanced Mucosal Melanoma Biological: JS001(Toripalimab Injection) Drug: Axitinib 1 MG [Inlyta] Other: JS001 and Axitinib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 99 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection Combined With Axitinib in the First-Line Treatment of Patients With Advanced Mucosal Melanoma
Actual Study Start Date : November 11, 2019
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma
Drug Information available for: Axitinib

Arm Intervention/treatment
Experimental: JS001(Toripalimab Injection) Combined With Axitinib Other: JS001 and Axitinib

Control Group:

Toripalimab (240 mg, IV, Q3W) is administered on the first day until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of no more than 2 years

Experimental: JS001 alone Biological: JS001(Toripalimab Injection)

Test Group:

Toripalimab (240 mg, IV, Q3W) + axitinib (5 mg/tablet, one tablet, twice a day, orally); axitinib is started on the second day of administration of toripalimab until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of toripalimab use of no more than 2 years.

Active Comparator: Axitinib alone Drug: Axitinib 1 MG [Inlyta]
Axitinib (5 mg/tablet) one tablet, twice a day, orally until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death

Primary Outcome Measures :
  1. the progression-free survival (PFS) [ Time Frame: 36 months ]
    Progression-free survival (PFS) per RECIST 1.1 criteria: Time from the date of randomization to the first documented disease progression (per RECIST 1.1 criteria), or death from any cause, whichever occurs first.

Secondary Outcome Measures :
  1. INV-ORR [ Time Frame: 36 months ]
    INV-ORR in crossover subjects is the number of subjects with DOR of CR or PR based on INV assessment divided by the number of crossover subjects. DOR is defined as the best response recorded as measured by INV from the date of the first crossover dose to the date of objective documentation of progression per RECIST 1.1 or the date of subsequent therapy, including tumor-directed radiotherapy and tumor-directed surgery, whichever occurs first. For subjects without documented progression or subsequent treatment, all available response designations will be assigned to the DOR evaluation. Baseline tumor assessments for crossover subjects are based on the last tumor assessment for monotherapy prior to the combination crossover. Exploratory endpoints will be analyzed at the time of primary endpoint analysis if data are available.

  2. ORR [ Time Frame: 36 months ]
    Objective response rate (ORR) according to RECIST 1.1;

  3. PFS [ Time Frame: 36 months ]
    Progression-free survival (PFS) according to RECIST 1.1;

  4. DOR [ Time Frame: 36 months ]
    Duration of response (DOR) according to RECIST 1.1;

  5. TTR [ Time Frame: 36 months ]
    Time to response (TTR) according to RECIST 1.1;

  6. DCR [ Time Frame: 36 months ]
    Disease control rate (DCR) according to RECIST 1.1;

  7. OS [ Time Frame: 36 months ]
    Overall survival (OS): Time from the date of randomization to death from any cause. Surviving patients as of the date of analysis will be censored at the date of their last contact.

  8. safety: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment [ Time Frame: 36 months ]
    Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria Patients are eligible for the trial if they meet the following criteria:

  1. Men and women, aged 18 to 80 years.
  2. Patients with pathohistologically confirmed, unresectable or metastatic mucosal melanoma.
  3. No prior treatment with any systemic antineoplastic agents (prior adjuvant or neoadjuvant therapy is allowed, but should be completed at least 3 weeks prior to randomization and all related adverse events have returned to normal or CTC-AE Grade 1).
  4. Have a score of 0 or 1 on the ECOG scale.
  5. Tumor tissue samples must be available for PD-L1 expression testing.
  6. At least one measurable lesion according to RECIST 1.1, and the lesion has not been irradiated.
  7. Organ function must meet the following requirements (within 7 days prior to randomization):

    Peripheral blood: absolute neutrophil count (ANC) ≥1.5 × 109/L, platelets (PLT) ≥100 × 109/L, hemoglobin (HB) ≥9 g/dL (no blood transfusion or blood components within 14 days before testing); Liver: Serum bilirubin (TBIL) ≤1.5 x upper limit of normal (ULN),, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 x ULN (≤5 x ULN in case of liver metastases); Serum creatinine ≤1.5 x ULN; International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤1.5 x ULN (only for patients not receiving anticoagulant therapy; patients receiving anticoagulant therapy should keep the anticoagulant within the therapeutic requirements); Normal cardiac function, i.e., normal or abnormal electrocardiogram without clinical significance, and left ventricular ejection fraction (LVEF) greater than 50% on cardiac ultrasound.

  8. Women of childbearing age must have a negative pregnancy test within 7 days prior to treatment; men of reproductive potential or women of childbearing potential must use highly effective contraceptive methods (e.g., oral contraceptives, intrauterine contraceptive devices, abstinence or barrier contraception in combination with spermicides) throughout the trial and continue contraception for 3 months after the end of treatment.
  9. Subjects are willing to participate in this study and sign informed consent form, have good compliance and cooperate with the follow-up.

Exclusion Criteria Patients with any of the following conditions will be excluded from the trial:

  1. Patients previously treated with anti-PD-1, anti-PD-L1, anti-PD-L2 therapy and/or VEGFR TKIs.
  2. Patients who have participated in or are participating in clinical trial of other drug/therapy within 4 weeks prior to this study treatment (before randomization).
  3. Major surgery, live vaccination, immunotherapy within 4 weeks prior to study start, and radiotherapy within 2 weeks prior to study start.
  4. History of malignancy other than mucosal melanoma within the past 3 years, with the exception of cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, early stage prostate cancer, and carcinoma in situ of the cervix.
  5. Patients who received hematopoietic stimulating factors, such as granulocyte colony-stimulating factor (G-CSF) and erythropoietin, within 1 week prior to study start.
  6. HIV test positive.
  7. Patients with active hepatitis B or C:

    • If HBsAg or HBcAb is positive, additionally test HBV DNA (results above the lower limit of detection at site);
    • If the result of HCV antibody test is positive, additionally test HCV RNA.
  8. Known to be allergic to recombinant humanized PD-1 monoclonal antibody drug and its components; known to be allergic to axitinib and any of its excipients.
  9. Hypertension that cannot be controlled by medication.
  10. Massive pleural effusion or ascites with clinical symptoms requiring symptomatic management.
  11. Subjects with active central nervous system (CNS) metastases are excluded. Subjects with metastatic brain lesions are eligible if they have received treatment and have no evidence of disease progression on magnetic resonance imaging (MRI) at least 8 weeks after completion of treatment and within 28 days before the first dose. Immunosuppressive doses of systemic corticosteroids (>10 mg/day prednisone equivalent) must not be required at least 2 weeks prior to study drug administration.
  12. History of active pulmonary tuberculosis.
  13. Have any uncontrollable clinical problems, including but not limited to:

    • Active autoimmune disease requiring systemic steroid/immunosuppressive therapy, such as hypophysitis, colitis, hepatitis, nephritis, etc.;
    • Have the following occurrence within 6 months prior to randomization: 1) deep vein thrombosis or pulmonary embolism; 2) percutaneous coronary intervention, acute coronary syndrome, coronary artery bypass grafting; 3) cerebrovascular accident, transient ischemic attack.
    • Other serious, uncontrollable concomitant illness that may affect protocol compliance or interfere with interpretation of results, including active opportunistic infection or progressive (severe) infection, uncontrolled diabetes, cardiovascular disease (New York Heart Association class III or IV heart failure, second degree or higher heart block, myocardial infarction within the past 6 months, unstable arrhythmia or unstable angina, cerebral infarction within 3 months, etc.) or pulmonary disease (history of interstitial pneumonia, obstructive pulmonary disease, and symptomatic bronchospasm).
  14. Any condition that affects the subject's swallowing of the drug, and any condition that affects the absorption or pharmacokinetics of the investigational product.
  15. Have received stem cell transplant or organ transplant.
  16. Women of childbearing age, pregnant or lactating women with positive serum or urine pregnancy test 7 days before starting treatment.
  17. Have a history of psychotropic drug abuse and unable to withdraw or have a history of mental disorders.
  18. Other severe, acute, or chronic medical conditions or laboratory abnormalities that, in the judgment of the investigator, may increase the risk associated with study participation or may interfere with the interpretation of study results.
  19. Patients who are judged by the investigator to have poor compliance, or other conditions that make them unsuitable for this trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03941795

Layout table for location contacts
Contact: Jun Guo, MD,PhD 010-88121122
Contact: Xinan Sheng, MD

Layout table for location information
China, Beijing
Beijing Cancer Hospital Recruiting
Beijing, Beijing, China, 100142
Contact: Jun Guo, MD,PHD    010-88121122   
Principal Investigator: Jun Guo, MD,PHD         
Sub-Investigator: Xinan Sheng, MD         
China, Liaoning
Baishen First Hospital of Jilin University Not yet recruiting
Shengyang, Liaoning, China
Contact: Di Wu, Professor    13944888991   
Sponsors and Collaborators
Beijing Cancer Hospital
Layout table for investigator information
Principal Investigator: Jun Guo, MD,PhD Beijing Cancer Hospital

Layout table for additonal information
Responsible Party: Jun Guo, Director of department of renal cancer and melanoma, Beijing Cancer Hospital Identifier: NCT03941795    
Other Study ID Numbers: BJCH-MM-0624
First Posted: May 8, 2019    Key Record Dates
Last Update Posted: December 6, 2019
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jun Guo, Beijing Cancer Hospital:
PD-1 monoclonal antibody
the First Line Therapy
Mucosal Melanoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action